Non-selective tyrosine kinase inhibitors (TKIs), such as afatinib, dacomitinib, and neratinib, exhibit poor antitumor activity against non-small cell lung cancer (NSCLC), and their efficacy may be linked to specific HER2 mutation types [125–128]. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.